Press "Enter" to skip to content

Preoperative Regulation Of Inflammation Might Stave Off Cancer Recurrences

A developing body of proof recommends that conventional cancer therapies can paradoxically endorse new tumor development. Now, a group of researchers spearheaded by Allison Gartung and Dipak Panigrahy at BIDMC (Beth Israel Deaconess Medical Center) of the Cancer Center has showed that management of anti-inflammatory therapies that avoid pro-resolution as well as inflammation treatments that tamp down the inflammatory response of body to chemotherapy or surgery can market long-term survival in experimental models of animal cancer.

The paper has been dubbed as the Editor’s Pick for this month and was posted online in The Journal of Clinical Investigation.

“Cancer treatment is a dual-edged sword, as dying cells of cancer can activate inflammation and market the development of cancerous microscopic cells,” claimed Panigrahy. “Chemotherapy, surgery, and radiation can all lure the body’s immunosuppressive or inflammatory injury response. Even anesthetics can damage the inflammation’s resolution.”

Panigrahy and associates, comprising Charles N. Serhan (director of the Center of Experimental Therapeutics) conjectured that a premature blockade of the inflammatory cascade and/or pacing the inflammation’s resolution can overtake the tumor-marketing cancer surgery’s unintended consequences. This novel method of jamming inflammation and/or pacing the inflammation’s resolution before surgery can also possibly advantage the more than 30% of people who do not suffer from cancer but shelter microscopic cancers—small sets of cancer cells that do not make a developing tumor.

On a related note, a computer-supported diagnostic process assists physicians know the development of low-grade brain tumors at smaller volumes and beforehand as compared to visual comparison, as per a study posted in the open-access PLOS Medicine journal by the University of Alabama’s Hassan Fathallah-Shaykh at Birmingham, and associates. On the other hand, extra clinical studies are required to decide whether premature therapeutic interventions turned on by early tumor development detection improve quality of life and extend survival times.

Author Details
SR. EDITOR At The Industry Today

Beatrice Doyle has studied a bachelor of technology in medical biotechnology and is a senior editor at our news portal. Beatrice is responsible for all the health and medical related content on our news portal. She aims at the drug approvals, innovation and technology, and lifestyle articles. Beatrice further looks to expand and diversify the portal’s capabilities in more scientific topics, which will provide all the content on one click. As an accomplished columnist, Beatrice leverages her deep data expertise, publisher knowledge, technological and innovation orientation to maximize the potential of portals integrated capabilities.